Photo from wikipedia
The approval of multitargeted anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) has been a success story for the management of advanced non-small-cell lung cancers (NSCLCs) over the last half… Click to show full abstract
The approval of multitargeted anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) has been a success story for the management of advanced non-small-cell lung cancers (NSCLCs) over the last half a decade, with the 1st generation TKI crizotinib approved in 2011 and 2nd generation ALK TKIs approved (ceritinib in 2014 and alectinib in 2016) for crizotinib-resistant disease. ALK rearrangements are present in 5% of NSCLCs and these fusion proteins act as driver oncogenes in those tumors; engaging pro-survival and anti-apoptotic signals through downstream signals including the phosphatidylinositol-3-kinase (PI3K), mitogen-activated protein kinase (MAPK) and signal transducer and activator of
Journal Title: Cell Cycle
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!